The €6.1 million project INNO4COV-19 is committed to supporting the commercialization of new products across Europe for combating COVID-19 over the next two years.
Looking for the fast development of products – from medical technologies to surveillance solutions – the project will boost innovation to tackle the new coronavirus, reinforcing Europe’s technological leadership, and invigorating an industrial sector capable of protecting citizens’ safety and well-being.
Officially starting on October 1, the virtual kick-off took place on October 6-7, counting with the support of two European Commission officers.
The 11-partner consortium led by INL – International Iberian Nanotechnology Laboratory, is looking for efficient and fast solutions that can help in the fight against COVID-19 jointly with the other actively involved industrial and RTO partners.
The mission of INNO4COV-19 is to create a “lab-to-fab” platform and a collaboration resource where companies and reference laboratories will find the tools for developing and implementing innovative technologies – from idea assessment to market exploitation. This work will be carried out as part the European Union Coronavirus initiative and in strong collaboration with all the funded projects where to accelerate the time to market for any promising product.
INNO4COV-19 is set to assist up to 30 test cases and applications from several areas spanning from Medical technologies, Environmental Surveillance systems, Sensors, Protection of Healthcare workers and Artificial Intelligence and Data mining. To achieve this, INNO4COV-19 is awarding half of the budget to support 30 enterprises selected through a set number of open calls during the first year of the project.
The first call will be launched in November 2020 across several platforms
For more information visit website: http://www.inno4cov19.eu/open-call/
Awardees will receive up to €100,000 each and benefit from the INNO4COV-19 consortium’s technical, regulatory, and business expertise.
You can find the latest on Inno4COVID-19 project at:
Please contact us at our email: email@example.com